LEADER 03550nam  22006375  450 
001 9910254504103321
005 20200704040748.0
010   $a3-319-26206-8
024 7 $a10.1007/978-3-319-26206-2
035   $a(CKB)3710000000596587
035   $a(EBL)4405610
035   $a(SSID)ssj0001653769
035   $a(PQKBManifestationID)16432952
035   $a(PQKBTitleCode)TC0001653769
035   $a(PQKBWorkID)14982590
035   $a(PQKB)10245838
035   $a(DE-He213)978-3-319-26206-2
035   $a(MiAaPQ)EBC4405610
035   $a(PPN)192219111
035   $a(EXLCZ)993710000000596587
100   $a20160210d2016      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aPractical Pharmacology for Alzheimer?s Disease /$fby Takashi Kudo, Kenneth L. Davis, Rafael Blesa Gonzalez, David George Wilkinson
205   $a1st ed. 2016.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016.
215   $a1 online resource (144 p.)
300   $aDescription based upon print version of record.
311   $a3-319-26204-1 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $aBasic theory of pharmacology for Alzheimer?s disease -- Practical Pharmacology of Donepezil -- Practical pharmacology of Galantamine -- Practical pharmacology of Rivastigmine -- Practical Pharmacology of Memantine -- How do we use Symptomatic drugs for Dementia.
330   $aThe wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer?s disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. However, the fact that clinical trials of these drugs have not yet yielded satisfactory results has meant that for the time being patients continue to be treated only with symptomatic drugs. Currently, four such drugs are available: donepezil, galantamine, rivastigmine, and memantine. In this book, the four leading experts on each of these drugs explain their practical pharmacology with the aim of providing a sound basis for their use, which to date has been of questionable proficiency. In addition, an introductory chapter considers the basic theory of pharmacology for Alzheimer?s disease and the book closes with an overview of the ways in which symptomatic drugs are used for dementia.
606   $aPsychopharmacology
606   $aNeurology 
606   $aPharmacotherapy
606   $aPsychopharmacology$3https://scigraph.springernature.com/ontologies/product-market-codes/H53010
606   $aNeurology$3https://scigraph.springernature.com/ontologies/product-market-codes/H36001
606   $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000
615  0$aPsychopharmacology.
615  0$aNeurology .
615  0$aPharmacotherapy.
615 14$aPsychopharmacology.
615 24$aNeurology.
615 24$aPharmacotherapy.
676   $a610
700   $aKudo$b Takashi$4aut$4http://id.loc.gov/vocabulary/relators/aut$01064625
702   $aDavis$b Kenneth L$4aut$4http://id.loc.gov/vocabulary/relators/aut
702   $aBlesa Gonzalez$b Rafael$4aut$4http://id.loc.gov/vocabulary/relators/aut
702   $aWilkinson$b David George$4aut$4http://id.loc.gov/vocabulary/relators/aut
906   $aBOOK
912   $a9910254504103321
996   $aPractical Pharmacology for Alzheimer?s Disease$92539787
997   $aUNINA